Trabectedin + PLD (recurrent ovarian, OVA-301)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN DRUG-TRABECTEDIN |
|---|
| ID | REG-TRABECTEDIN-PLD-OVARIAN |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-OVA-301-MONK-2010 |
Notes
OVA-301 phase 3: overall mPFS 7.3 vs 5.8 mo (HR 0.79); benefit largest in partially-platinum-sensitive (PFI 6-12 mo) subgroup — mPFS 7.4 vs 5.5 mo (HR 0.65), mOS 23.0 vs 17.1 mo (HR 0.59). Used in 3L+ where re-platinum is undesirable (cumulative neuropathy, hypersensitivity, short PFI). Mandatory central venous access for trabectedin (24-h infusion option in sarcoma; 3-h for ovarian per OVA-301). Cumulative anthracycline tracking: stop PLD at lifetime ~550 mg/m².
Used By
Indication
IND-OVARIAN-3L-TRABECTEDIN-PLD- IND-OVARIAN-3L-TRABECTEDIN-PLD